New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
09:12 EDTEXAS, KBH, RBCN, HZNP, ORCL, RENN, PSUN, OWWOn The Fly: Pre-market Movers
UP AFTER EARNINGS: KB Home (KBH), up 7%...Pacific Sunwear (PSUN), up 7%. ALSO HIGHER: Horizon Pharma (HZNP), up 23% after deal to acquire Ireland's Vidara Therapeutics through reverse merger... Exact Sciences (EXAS), up 6.5% after a clinical trial of its Cologuard test, which it co-developed with the Mayo Clinic, showed "unprecedented" rates of precancer and cancer detection by a noninvasive test... DOWN AFTER EARNINGS: Oracle (ORCL), down 3.3%... Renren (RENN), down 7%. ALSO LOWER: Orbitz (OWW), down 5.4% after Goldman downgraded shares to Sell from Neutral... Rubicon (RBCN), down 6% after 2.5M share spot secondary offering priced at $13.00.
News For OWW;ORCL;KBH;PSUN;HZNP;EXAS;RENN;RBCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
07:39 EDTORCLOracle volatility elevated into Q1 and outlook
Subscribe for More Information
August 27, 2015
10:06 EDTORCLCiti sees Workday guidance confusion as opportunity to buy
Subscribe for More Information
07:22 EDTHZNPHorizon Pharma granted Notice of Allowance for Pennsaid by USPTO
Subscribe for More Information
August 26, 2015
15:49 EDTEXASExact Sciences says CMS advisors vote to maintain Cologuard reimbursement rate
Subscribe for More Information
06:44 EDTORCLWorkday valuation contingent on competitors in cloud market, WSJ reports
Subscribe for More Information
August 25, 2015
19:16 EDTORCLTV service Hulu to feature programmatic ads powered by Facebook, Oracle
Subscribe for More Information
11:23 EDTOWWAnalyst says Priceline undervalued, looks poised to outperform
Subscribe for More Information
07:24 EDTORCLRentrak weakness a buying opportunity, says Brean Capital
Subscribe for More Information
August 24, 2015
08:00 EDTEXASExact Sciences price target lowered to $26 from $32 at Canaccord
Canaccord lowered its price target on Exact Sciences to $26 from $32 to reflect dilution of the large secondary offering. The firm maintains its Buy rating on Exact Sciences shares, citing its sales force expansion, payer traction and a high probability of a positive outcome from the USPSTF decision.
August 21, 2015
13:04 EDTHZNPDepomed to file revocation statement with SEC
Subscribe for More Information
August 20, 2015
11:49 EDTORCLOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX
08:32 EDTORCLOracle agrees to acquire Maxymiser
Subscribe for More Information
07:03 EDTHZNPHorizon Pharma issued Notice of Allowance by USPTO covering Vimovo
Subscribe for More Information
August 19, 2015
17:40 EDTHZNPDepomed sends letter to Horizon Pharma CEO
Subscribe for More Information
17:36 EDTHZNPDepomed board unanimously rejects revised proposal from Horizon Pharma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use